Regulation of Hepcidin by Erythropoiesis: The Story so Far

Annual Review of Nutrition

Volumn 36, Issue , 2016, Pages 417-434

  Pasricha, Sant Rayn ^a   McHugh, Kirsty ^b   Drakesmith, Hal ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Erythroferrone; Erythropoiesis; Hepcidin; Iron; Thalassemia

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; COMPLEMENT COMPONENT C1Q; ERYTHROPOIETIN; FERROPORTIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; HORMONE; IRON; TRANSFERRIN; TUMOR NECROSIS FACTOR; TWISTED GASTRULATION FACTOR 1; UNCLASSIFIED DRUG; FAM132B PROTEIN, HUMAN; HAMP PROTEIN, HUMAN; LIGAND; PEPTIDE HORMONE;

ANEMIA; BETA THALASSEMIA; CARBOXY TERMINAL SEQUENCE; ERYTHROBLAST; ERYTHROPOIESIS; FAM132B GENE; GENE; GENE MUTATION; GENE PRODUCT; HOMEOSTASIS; HUMAN; HYPOXIA; INFLAMMATION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON HOMEOSTASIS; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; TRANSFERRIN BLOOD LEVEL; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CYTOLOGY; DOWN REGULATION; EVIDENCE BASED MEDICINE; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; SECRETION (PROCESS); UPREGULATION;

ANIMALS; DOWN-REGULATION; ERYTHROPOIESIS; EVIDENCE-BASED MEDICINE; HEMATOPOIETIC STEM CELLS; HEPCIDINS; HOMEOSTASIS; HUMANS; IRON; LIGANDS; MODELS, BIOLOGICAL; PEPTIDE HORMONES; UP-REGULATION;

EID: 84979022072     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071715-050731     Document Type: Review

References (100)

1. Altamura S, Kessler R, Gröne HJ, Gretz N, Hentze MW, et al. 2014. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload. Cell Metab. 20:359-67
2. Anderson ER, Taylor M, Xue X, Ramakrishnan SK, Martin A, et al. 2013. Intestinal HIF2αpromotes tissue-iron accumulation in disorders of iron overload with anemia. PNAS 110:E4922-30
3. Andrews NC. 1999. Disorders of iron metabolism. N. Engl. J. Med. 341:1986-95
4. Andriopoulos B Jr., Corradini E, Xia Y, Faasse SA, Chen S, et al. 2009. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat. Genet. 41:482-87
5. Armitage AE, Eddowes LA, Gileadi U, Cole S, Spottiswoode N, et al. 2011. Hepcidin regulation by innate immune and infectious stimuli. Blood 118:4129-39
6. Arnold K, Bordoli L, Kopp J, Schwede T. 2006. The SWISS-MODEL workspace a web-based environment for protein structure homology modelling. Bioinformatics 22:195-201
7. Ashby DR,Gale DP, Busbridge M, Murphy KG,Duncan ND, et al. 2010. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 95:505-8
8. Babitt JL, Lin HY. 2011. The molecular pathogenesis of hereditary hemochromatosis. Semin. Liv. Dis. 31:280-92
9. Bardou-Jacquet E, Ben Ali Z, Beaumont-Epinette MP, Loreal O, Jouanolle AM, Brissot P. 2014. Non-HFE hemochromatosis: pathophysiological and diagnostic aspects. Clin. Res. Hepatol. Gastroenterol. 38:143-54
10. Benkert P, Tosatto SC, Schomburg D. 2008. QMEAN a comprehensive scoring function for model quality assessment. Proteins 71:261-77
11. Besson-Fournier C, Latour C, Kautz L, Bertrand J, Ganz T, et al. 2012. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood 120:431-39
12. Boudko SP, Sasaki T, Engel J, Lerch TF, Nix J, et al. 2009. Crystal structure of human collagen XVIII trimerization domain a novel collagen trimerization Fold. J. Mol. Biol. 392:787-802
13. Calis JC, Phiri KS, Faragher EB, Brabin BJ, Bates I, et al. 2008. Severe anemia in Malawian children. N. Engl. J. Med. 358:888-99
14. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. 2014. Guidelines for the Management of Transfusion Dependent Thalassaemia. Cyprus: Thalass. Int. Fed
15. Casals-Pascual C, Huang H, Lakhal-Littleton S, Thezenas ML, Kai O, et al. 2012. Hepcidin demonstrates a biphasic association with anemia in acute Plasmodium falciparum malaria. Haematologica 97:1695-98
16. Casals-Pascual C, Kai O, Cheung JO, Williams S, Lowe B, et al. 2006. Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. Blood 108:2569-77
17. Casanovas G, Swinkels DW, Altamura S, Schwarz K, Laarakkers CM, et al. 2011. Growth differentiation factor 15 in patients with congenital dyserythropoietic anaemia (CDA) type II. J. Mol. Med. 89:811-16
18. Casanovas G, Vujic SpasicM, Casu C, Rivella S, Strelau J, et al. 2012. Themurine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 98:444-47
19. Chaston TB, Matak P, Pourvali K, Srai SK, McKie AT, Sharp PA. 2011. Hypoxia inhibits hepcidin expression in HuH7 hepatoma cells via decreased SMAD4 signaling. Am. J. Physiol. Cell Physiol. 300:C888-95
20. Díaz V, Gammella E, Recalcati S, Santambrogio P,Naldi AM, et al. 2013. Liver iron modulates hepcidin expression during chronically elevated erythropoiesis in mice. Hepatology 58:2122-32
21. Drakesmith H, Schimanski LM,Ormerod E, Merryweather-Clarke AT, Viprakasit V, et al. 2005. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106:1092-97
22. EckMJ, Sprang SR. 1989. The structure of tumor necrosis factor-alpha at 2.6A resolution. Implications for receptor binding. J. Biol. Chem. 264:17595-605
23. Erlandson ME,Walden B, SternG,HilgartnerMW,Wehman J, Smith CH. 1962. Studies on congenital hemolytic syndromes, IV. Gastrointestinal absorption of iron. Blood 19:359-78
24. Finberg KE, Heeney MM, CampagnaDR, Aydinok Y, Pearson HA, et al. 2008. Mutations inTMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat. Genet. 40:569-71
25. FinbergKE, Whittlesey RL,FlemingMD,AndrewsNC.2010. Down-regulation ofBmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis. Blood 115:3817-26
26. Finch C. 1994. Regulators of iron balance in humans. Blood 84:1697-702
27. Folgueras AR, de Lara FM, Pendás AM, Garabaya C, Rodríguez F, et al. 2008. Membrane-bound serine protease matriptase-2 (Tmprss6) is an essential regulator of iron homeostasis. Blood 112:2539-45
28. Frazer DM, Wilkins SJ, Darshan D, Badrick AC, McLaren GD, Anderson GJ. 2012. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression. Br. J. Haematol. 157:615-26
29. Ganz T. 2011. Hepcidin and iron regulation, 10 years later. Blood 117:4425-33
30. Ganz T. 2013. Systemic iron homeostasis. Physiol. Rev. 93:1721-41
31. Ganz T, Nemeth E. 2012. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb. Perspect. Med. 2:a011668
32. Gardenghi S, Grady RW, Rivella S. 2010. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol. Oncol. Clin. North Am. 24:1089-107
33. Gardenghi S, Renaud TM, Meloni A, Casu C, Crielaard BJ, et al. 2014. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood 123:1137-45
34. Gordeuk VR, Miasnikova GY, Sergueeva AI, Niu X, Nouraie M, et al. 2011. Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood 118:5278-82
35. GuidaC, Altamura S, Klein FA,Galy B, BoutrosM, et al. 2015. A novel inflammatory pathwaymediating rapid hepcidin-independent hypoferremia. Blood 125:2265-75
36. Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, et al. 2015. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Blood 125:873-80
37. Jonker FAM, Calis JCJ, Phiri K, Kraaijenhagen RJ, Brabin BJ, et al. 2013. Low hepcidin levels in severely anemic Malawian children with high incidence of infectious diseases and bone marrow iron deficiency. PLOS ONE 8:e78964
38. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, et al. 2006. The effects of erythropoietic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 91:809-12
39. Kautz L, Jung G, Du X, Gabayan V, Chapman J, et al. 2015. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood 126:2031-37
40. Kautz L, Jung G, Nemeth E, Ganz T. 2014. Erythroferrone contributes to recovery from anemia of inflammation. Blood 124:2569-74
41. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. 2014. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 46:678-84
42. Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, et al. 2008. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112:1503-9
43. Kautz L, Nemeth E. 2014. Molecular liaisons between erythropoiesis and iron metabolism. Blood 124:479-82
44. Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, et al. 2007. Urinary hepcidin in congenital chronic anemias. Pediatr. Blood Cancer 48:57-63
45. Kim A, Nemeth E. 2015. New insights into iron regulation and erythropoiesis. Curr. Opin. Hematol. 22:199-205
46. Lakhal S, Schödel J, Townsend ARM, Pugh CW, Ratcliffe PJ, Mole DR. 2011. Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis. J. Biol. Chem. 286:4090-97
47. Lesbordes-Brion JC, Viatte L, Bennoun M, Lou DQ, Ramey G, et al. 2006. Targeted disruption of the hepcidin 1 gene results in severe hemochromatosis. Blood 108:1402-5
48. Liu Q, Davidoff O, Niss K, Haase VH. 2012. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Investig. 122:4635-44
49. Mastrogiannaki M, Matak P, Mathieu JRR, Delga S, Mayeux P, et al. 2012. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica 97:827-34
50. Merryweather-Clarke AT, Atzberger A, Soneji S, Gray N, Clark K, et al. 2011. Global gene expression analysis of human erythroid progenitors. Blood 117:e96-108
51. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. 2009. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat. Genet. 41:478-81
52. Min X, Lemon B, Tang J, Liu Q, Zhang R, et al. 2012. Crystal structure of a single-chain trimer of human adiponectin globular domain. FEBS Lett. 586:912-17
53. Nai A, Pellegrino RM, Rausa M, Pagani A, Boero M, et al. 2014. The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice. Haematologica 99:1016-21
54. Nemeth E, Rivera S,Gabayan V, KellerC,Taudorf S, et al. 2004. IL-6mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Investig. 113:1271-76
55. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, et al. 2004. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090-93
56. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. 2003. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101:2461-63
57. PakM, LopezMA, Gabayan V,Ganz T, Rivera S. 2006. Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108:3730-35
58. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald ML, Franchini PL, et al. 2004. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet. 36:77-82
59. Parrow NL, Fleming RE. 2014. Bone morphogenetic proteins as regulators of iron metabolism. Annu. Rev. Nutr. 34:77-94
60. Pasricha SR, Atkinson SH, Armitage AE, Khandwala S, Veenemans J, et al. 2014. Expression of the iron hormone hepcidin distinguishes different types of anemia in African children. Sci. Transl. Med. 6:235re3
61. Pasricha SR, Frazer DM, Bowden DK, Anderson GJ. 2013. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major a longitudinal study. Blood 122:124-33
62. Pasricha SR, McQuilten Z, Westerman M, Keller A, Nemeth E, et al. 2011. Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica 96:1099-105
63. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, et al. 2007. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Investig. 117:1926-32
64. Pietrangelo A. 2004. The ferroportin disease. Blood Cells Mol. Dis. 32:131-38
65. Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, et al. 2008. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBP and alpha;. Blood 111:5727-33
66. Piperno A,Galimberti S,MarianiR, Pelucchi S,RavasiG, et al. 2011. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood 117:2953-59
67. Porter JB. 2009. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin 33:S37-45
68. Porter JB,GarbowskiM. 2014. The pathophysiology of transfusional iron overload. Hematol. Oncol. Clin. North Am. 28:683-701
69. Pospíilová D, Houda J, Holub D, Ludíková B, Mojzíková R, et al. 2012. Significance of hepcidin level assessment in the diagnosis of selected types of anaemia in childhood. Transfuze Hematol. Dnes. 18:58-65
70. Premawardhena A, Fisher CA, Olivieri NF, de Silva S, ArambepolaM, et al. 2005. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 366:1467-70
71. Prentice AM,Doherty CP, Abrams SA, Cox SE, Atkinson SH, et al. 2012. Hepcidin is themajor predictor of erythrocyte iron incorporation in anemic African children. Blood 119:1922-28
72. Rees DC, Styles L, Vichinsky EP, Clegg JB,Weatherall DJ. 1998. The hemoglobin E syndromes. Ann. N. Y. Acad. Sci. 850:334-43
73. Ressl S, Vu BK, Vivona S,Martinelli DC, Sudhof TC, Brunger AT. 2015. Structures of C1q-like proteins reveal unique features among the C1q/TNF superfamily. Structure 23:688-99
74. Richards AA, Stephens T, Charlton HK, Jones A, Macdonald GA, et al. 2006. Adiponectin multimerization is dependent on conserved lysines in the collagenous domain: evidence for regulation of multimerization by alterations in posttranslational modifications. Mol. Endocrinol. 20:1673-87
75. Robach P, Recalcati S,Girelli D, CampostriniN,Kempf T, et al. 2013. Serum hepcidin levels and muscle iron proteins in humans injected with low-or high-dose erythropoietin. Eur. J. Haematol. 91:74-84
76. Roettol A, Papanikolaou G, Politou M, Alberti F, Girelli D, et al. 2003. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat. Genet. 33:21-22
77. Ross SL, Tran L,Winters A, Lee KJ, Plewa C, et al. 2012. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. CellMetab. 15:905-17
78. Seldin MM, Lei X, Tan SY, Stanson KP,Wei Z, Wong GW. 2013. Skeletal muscle-derived myonectin activates the mammalian target of rapamycin (mTOR) pathway to suppress autophagy in liver. J. Biol. Chem. 288:36073-82
79. Seldin MM, Peterson JM, Byerly MS,Wei Z, Wong GW. 2012. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J. Biol. Chem. 287:11968-80
80. Seldin MM, Tan SY, Wong GW. 2014. Metabolic function of the CTRP family of hormones. Rev. Endocr. Metab. Disord. 15:111-23
81. Shapiro L, Scherer PE. 1998. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8:335-38
82. Sheeran C, Weekes K, Shaw J, Pasricha SR. 2014. Complications of HbH disease in adulthood. Br. J. Haematol. 167:136-39
83. Shemin D, Rittenberg D. 1946. The lifespan of the human red blood cell. J. Biol. Chem. 166:627-36
84. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. 2008. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 8:502-11
85. Smith CL, Arvedson TL, Cooke KS, Dickmann LJ, Forte C, et al. 2013. IL-22 regulates iron availability in vivo through the induction of hepcidin. J. Immunol. 191:1845-55
86. Sonnweber T, Nachbaur D, Schroll A,NairzM, Seifert M, et al. 2014. Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB. Gut 63:1951-59
87. Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, et al. 2012. Regulation of hepcidin expression at high altitude. Blood 119:857-60
88. Tamary H, Shalev H, Perez-Avraham G, Zoldan M, Levi I, et al. 2008. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 112:5241-44
89. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, et al. 2007. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13:1096-101
90. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, et al. 2009. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114:181-86
91. Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, et al. 2011. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 140:2044-55
92. Truksa J, Lee P, Beutler E. 2009. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 113:688-95
93. Truksa J, Lee P, Peng H, Flanagan J, Beutler E. 2007. The distal location of the iron responsive region of the hepcidin promoter. Blood 110:3436-37
94. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. 2002. Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J. Biol. Chem. 277:29359-62
95. Verga Falzacappa MV, Casanovas G, Hentze MW, Muckenthaler MU. 2008. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J. Mol. Med. 86:531-40
96. VokurkaM, Krijt J, Šulc K, Nečas E. 2006. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol. Res. 55:667-74
97. Wang Y, Lam KS, Chan L, Chan KW, Lam JB, et al. 2006. Post-translational modifications of the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high molecular weight oligomeric complex. J. Biol. Chem. 281:16391-400
98. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. 2008. Molecular, biochemical and functional characterizations of C1q/TNF family members adipose-tissue-selective expression patterns, regulation by PPAR-γagonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem. J. 416:161-77
99. Zhang DL, Senecal T, Ghosh MC, Ollivierre-Wilson H, Tu T, Rouault TA. 2011. Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood 118:2868-77
100. Zimmermann MB, Fucharoen S,Winichagoon P, Sirankapracha P,Zeder C, et al. 2008. Iron metabolism in heterozygotes for hemoglobinE (HbE),α-thalassemia 1, orβ-thalassemia and in compound heterozygotes for HbE/β-thalassemia1′2′3. Am. J. Clin. Nutr. 88:1026-31